Seaport Therapeutics
Summary ipo Updated Apr 30, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Seaport Therapeutics is a clinical-stage biotechnology company developing oral therapies for neuropsychiatric disorders, including depression, anxiety, and other central nervous system conditions 1. The company uses its proprietary Glyph platform — a lymphatic-targeting prodrug technology designed to improve oral bioavailability and reduce first-pass metabolism — to reformulate clinically validated mechanisms into differentiated product candidates 1. Seaport is headquartered in Boston, Massachusetts and was founded in 2024 by Daphne Zohar (formerly founding CEO of PureTech Health and co-founder of Karuna Therapeutics) and Steven M. Paul, M.D. (former CEO of Karuna Therapeutics and former President of Lilly Research Laboratories) 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2024-04-09 | Series A | $100M | ARCH Venture Partners, Sofinnova Investments | Third Rock Ventures, PureTech Health 1 |
| 2026-04-30 | IPO | $254.9M | Goldman Sachs (bookrunner) | J.P. Morgan, Leerink Partners, Citigroup, Stifel 23 |
The company priced its upsized initial public offering of 14,160,000 shares at $18.00 per share on April 30, 2026, for gross proceeds of approximately $254.9 million 2. Common stock began trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker symbol “SPTX” 23. Underwriters were granted a 30-day option to purchase up to an additional 2,124,000 shares 2. Upon closing, PureTech Health holds 16,685,013 shares of Seaport common stock 2.
What Investors Say
No verified investor quotes available at this time.
What Founders Say
No verified founder quotes available at this time.
Sources
-
Seaport Therapeutics, “Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines,” April 9, 2024. Accessed April 2026. https://seaporttx.com/press-release/seaport-therapeutics-launches-with-100-million-oversubscribed-series-a-financing-round-to-advance-novel-neuropsychiatric-medicines/↩↩↩↩
-
Investegate / PureTech Health, “PureTech’s Seaport Prices Upsized IPO Nasdaq: SPTX,” April 30, 2026. Accessed April 2026. https://www.investegate.co.uk/announcement/rns/puretech-health–prtc/puretech-s-seaport-prices-upsized-ipo-nasdaq-sptx/9548005↩↩↩↩↩
-
Bloomberg, “Antidepressant Maker Seaport Prices IPO at $18, Valuing Firm at $912 Million,” May 1, 2026. Accessed April 2026. https://www.bloomberg.com/news/articles/2026-05-01/antidepressant-maker-seaport-raises-255-million-in-upsized-ipo↩↩